Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
RaQualia Pharma 9-Mos Loss Y493.00M Vs Loss Y568.00M
RaQualia Pharma Inc. (4579.TO) Japan Nine Months Ended September 30 GROUP 2026 2025 Revenue Y2.35 bln Y2.31 bln Operating Profit (Y238.00 mln) (Y344.00 mln) Pretax Profit (Y261.00 mln) (Y426.00 mln) Net Profit (Y493.00 mln) (Y568.00 mln) Per share…
Kubota Pharma 9-Mos Loss Y908.00M Vs Loss Y435.00M
Kubota Pharmaceutical Holdings Co. Ltd. (4596.TO) Japan Nine Months Ended September 30 GROUP 2026 2025 Revenue Y11.00 mln Y18.00 mln Operating Profit (Y911.00 mln) (Y654.00 mln) Pretax Profit (Y908.00 mln) (Y435.00 mln) Net Profit (Y908.00 mln)…
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $91.00
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its target price raised by investment analysts at Morgan Stanley from $88.00 to $91.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an 'overweight' rating on…
Royalty Pharma (NASDAQ:RPRX) Stock Rating Upgraded by Zacks Research
Royalty Pharma (NASDAQ:RPRX - Get Free Report) was upgraded by equities researchers at Zacks Research from a 'hold' rating to a 'strong-buy' rating in a research note issued to investors on Wednesday, Zacks reports. How Royalty Pharma Prints Cash…
Ascendis Pharma A/S's (ASND) 'Outperform' Rating Reaffirmed at Royal Bank Of Canada
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its 'outperform' rating reaffirmed by stock analysts at Royal Bank Of Canada in a report issued on Friday, Benzinga reports. They currently have a $290.00 target price on the…
Spyglass Pharma (NASDAQ:SGP) Stock Price Target Raised at Stifel Nicolaus
Spyglass Pharma (NASDAQ:SGP - Get Free Report) had its price objective upped by stock analysts at Stifel Nicolaus from $42.00 to $44.00 in a research note issued on Friday, Benzinga reports. The firm presently has a 'buy' rating on the stock.
Ascendis Pharma A/S (NASDAQ:ASND) Given New $315.00 Price Target at UBS Group
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target hoisted by research analysts at UBS Group from $269.00 to $315.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a 'buy' rating on the…
Ascendis Pharma A/S (NASDAQ:ASND) Given New $352.00 Price Target at TD Cowen
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its target price lifted by stock analysts at TD Cowen from $341.00 to $352.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a 'buy' rating on the…
Ascendis Pharma A/S (NASDAQ:ASND) Given New $315.00 Price Target at Cantor Fitzgerald
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target upped by investment analysts at Cantor Fitzgerald from $300.00 to $315.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an 'overweight'…
Canaccord Genuity Group Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target upped by analysts at Canaccord Genuity Group from $268.00 to $274.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a 'hold'…
HC Wainwright Has Lowered Expectations for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price objective dropped by HC Wainwright from $344.00 to $335.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a 'buy' rating on the biotechnology…
Why Community Oncology Data Is A Blind Spot In Precision Medicine
Jason Baroff, Managing Partner – Ascend Technologies Group and MiBA Analytics. Precision oncology runs on a simple promise: The right test leads to the right therapy for the right patient. Over the past decade, I've seen many…
Indian Stock Market Falls: Sensex, Nifty Drop Amid Rising Inflation & Rate Hike Fears
Indian equity markets, including the Sensex and Nifty, experienced a significant downturn in early trade, driven by profit-taking and growing concerns over retail inflation surging past the Reserve Bank of India's tolerance limit, prompting…
Exagen: Q3 Raises Questions About The Turnaround (Rating Downgrade)
Exagen is downgraded to Hold as Q3 results reveal slower revenue growth, weaker margins, and higher operating losses, clouding the turnaround outlook. XGN's Q3 revenue grew 7% year-over-year but declined 8% sequentially, with gross margin slipping…
Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug
Pfizer partners with Blackstone, securing up to $1.5bn in funding for berobenatide, a potential first-in-class monthly GLP-1 agonist for obesity. PFE faces stagnant revenues, heavy debt, and looming patent expiries on key drugs, making GLP-1…
Receive a Daily briefing on Pharma Industry News
Get Started